A Phase 1b/2 Study of AV-299 (Formerly SCH 900105) in Combination With Gefitinib in Asian Subjects With Non-Small Cell Lung Cancer (P06162)

Trial Profile

A Phase 1b/2 Study of AV-299 (Formerly SCH 900105) in Combination With Gefitinib in Asian Subjects With Non-Small Cell Lung Cancer (P06162)

Completed
Phase of Trial: Phase I/II

Latest Information Update: 01 Jul 2018

At a glance

  • Drugs Ficlatuzumab (Primary) ; Gefitinib (Primary)
  • Indications Adenocarcinoma; Non-small cell lung cancer; Solid tumours
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors AVEO Oncology
  • Most Recent Events

    • 01 Jul 2018 Results (n=15) of phase 1 published in the Clinical Pharmacology in Drug Development.
    • 07 Apr 2015 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.
    • 29 Sep 2014 Results of a retrospective exploratory analysis in VeriStrat-selected patients with NSCLC were presented at the 2014 Congress of the European Society for Medical Oncology (ESMO), according to an AVEO Oncology media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top